Jazz Pharmaceuticals (JAZZ) Issues Long-Term Vision and Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. USO
3. SPY
4. BBIO
5. NVDA
6. OPCH
7. SKYD
8. GOOGL
9. AMD
10. STZ

Go back to Jazz Pharmaceuticals (JAZZ) Issues Long-Term Vision and Guidance

Jazz Pharmaceuticals Announces Vision 2025 to Deliver Sustainable Growth and Enhanced Value to Drive Transformation to Innovative, Global Biopharmaceutical Leader

January 10, 2022 7:30 AM EST

DUBLIN, Jan. 10, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced its Vision 2025 to deliver sustainable growth and enhanced value. Vision 2025 includes the following expectations: 1) generating $5 billion in revenue in 2025; 2) approval of at least five additional novel products by the end of the decade; and 3) realizing a 5% adjusted operating margin1 improvement from 2021 to 2025, driven by operational excellence. The Company also confirmed that it expects to meet its previously announced 2021 revenue guidance range of $3.02 to $3.1 billion and its net product sales guidance for neuroscience and oncology.2

Jazz ended 2021 demonstrating executional excellence... More